Immunological Efficacy of Vaccination against COVID-19 in Employees of Medical Institutions of Various Profiles: Psychiatric Hospital and Regional Hospital

Relevance. On the territory of the Russian Federation, mass vaccination of the population is recognized as a priority health strategy against COVID-19, Gam-COVID-Vac vaccine has been widely used. The main risk group, which is subject to priority vaccination, are employees of medical organizations (MO). The determination of IgG to SARS-CoV-2 is an important parameter for assessing the intensity and duration of post-vaccination immunity

Aims. Study the immunological efficacy of the vaccine Gam-COVID-Vac used by employees of a psychiatric hospital and a regional hospital.

Materials and methods. A study of the blood sera of 410 employees of two MO of various profiles who received one full course of the Gam-COVID-Vac» vaccine for the presence of IgG to RBD Spike SARS-CoV-2 using a set of reagents «SARS-CoV-2-IgG quantitative-ELISA-BEST» and IgG to NC SARS-CoV-2 using a set of reagents «ELISA anti-SARS-CoV-2 IgG».

Results and discussion. Specific IgG to RBD Spike SARS-CoV-2 after vaccination with «Gam-COVIDVac » were found in 92.9% of psychiatric hospital staff and 98.0% of the regional hospital. Antibodies of class G to SARS-CoV-2 with a level of 300 BAU/ml or more were detected in 11.6% of psychiatric hospital staff and in 70.0% of regional hospitals, which is associated with the smallest proportion of persons in a psychiatric hospital with hybrid immunity than in a regional hospital (67.4% vs. 89.0%, respectively). A study of employees of the Ministry of Defense of various profiles revealed a difference in the level of IgG to RBD Spike SARS-CoV-2: 178.0 BAU/ml in a psychiatric hospital and 366.0 BAU/ml in a regional hospital. In a psychiatric hospital, the IgG level was highest up to 3 months after the completed vaccination – 166.4 BAU/ml, in a regional hospital from 3 to 6 months – 362.8 BAU/ml, then the number of antibodies decreases, which indicates the importance of monitoring for class G antibodies to SARS-CoV-2 at different times after vaccinations. Among the employees of the two MO, mild forms of the COVID-19 disease prevailed.

Conclusion. Thus, the high immunological effectiveness of vaccination against COVID-19 with Gam-COVID-Vac was established in a group of employees of two MO, and the need for serological monitoring for the purpose of revaccination was also shown.

1. Feldblum I.V., Repin T.M., Devyatkov M.Yu., et al. Preventive effectiveness of domestic vaccines against a new coronavirus infection during immunization of employees of medical organizations. Epidemiology and Vaccination Prevention. 2023; 22(1):22–27 (In Russ). doi: 10.31631/2073-3046-2023-22-1-22-27

2. Platonova T.A., Golubkova A.A., Sklyar M.S., et al. On the issue of evaluating the effectiveness of vaccination of employees of medical organizations against COVID-19. Epidemiology and Vaccination Prevention. 2022;21(1): 61–66 (In Russ). doi: 10.31631/2073-3046-2022-21-1-61-66

3. Andreev I.V., Nechai K.O., Andreev A.I., et al. Post-vaccination and post-infectious humoral immune response to SARS-CoV-2 infection. Immunology. 2022; 43 (1): 18–32. (In Russ). doi: 10.33029/0206- 4952-2022-43-1-18-32

4. Kharchenko E.P. The pandemic continues: omicrons, long-term covid, vaccination and vaccines. Epidemiology and Vaccination Prevention. 2022;21(5):120–137. (In Russ). doi: 10.31631/2073-3046-2022-21-5-120-137

5. Gushchin V., Pochtovyi A., Kustova D., et al. Dynamics of SARS-CoV-2 Major Genetic Lineages in Moscow in the Context of Vaccine Prophylaxis. Int J Mol Sci. 2022;23(23):14670. doi: 10.3390/ijms232314670.

6. Stoma I., Korsak K., Voropaevet EV, et al. Comparative study of immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in Belarus. medRxiv. 2022;9(11):е21877. doi: 10.1101/2022.02.05.22270499

7. Ermolovich M.A., Kolodkina V.L., Samoilovich E.O., et al. Post-infectious and post-vaccination humoral immune response in adults with COVID-19: qualitative and quantitative assessment. Epidemiology and Vaccination Prevention. 2023;22(3):50–56. (In Russ). doi: 10.31631/2073-3046-2023-22-3-50-56

8. Nechai K.O., Andreev A.I., Andreev I.V., et al. Dynamic assessment of the intensity of the immune response to SARS-CoV-2 infection and immunization against COVID-19 with the Sputnik V vaccine. Immunology. 2023; 44(2):157–166. (In Russ). doi: 10.33029/0206-4952-2023-44-2-157-166.

9. Chistyakova G.N., Malgina G.B., Ustyuzhanin A.V., Remizova I.I. Formation of anti-infectious and post-vaccination humoral immunity to SARS-CoV-2 in medical workers of the perinatal center // Infection and immunity. 2022;12(4):688–700. (In Russ). doi: 10.15789/2220-7619-FOA-1856.

10. Isho B., Abe K., Zuo M., Jamal A., Rathod B. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci. Immunol. 2020;5:eabe5511. doi: 10.1126/sciimmunol.abe5511

11. Iyer A.S., Jones F.K., Nodoushani A., Kelly M., Becker M. - Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci. Immunol. 2020; 5(52):eabe0367. doi: 10.1126/sciimmunol.abe0367

12. Wajnberg A., Amanat F., Firpo A., et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370:1227–1230. doi: 10.1126/science.abd7728

13. Toptygina A.P., Semikina E.L., Zakirov R.Sh., Afridonova Z.E. Comparison of humoral and cellular immunity in patients with COVID-19 // Infection and immunity. 2022; 12(3):495–504. (In Russ). doi: 10.15789/2220-7619-COT-1809

14. Calculator of the confidence interval of binomial probability. Electronic resource. Available at: https://www.danielsoper.com/statcalc/calculator.aspx?id=85

15. New coronavirus infection COVID-19: professional aspects of health and safety of medical workers: methodological recommendations / edited by I.V. Bukhtiyarov, Yu.Yu. Gorblyansky. – M. : AMT, FGBNU «Research Institute of MT». 2021. – 132 p. (In Russ). ISBN 987-5-6042929-7-6.

16. Agafonova E.V., Kulikov S.N., Reshetnikova I.D., et al. Results of the study of seroprevalence to SARS-CoV-2 in medical workers: age and professional aspects. Epidemiology and Vaccination Prevention. 2021;20(2):49–57. (In Russ). doi: 10.31631/2073-3046-2021-20-2-49-57

17. Kuzmenko S.A., Likstanov M.I., Oshlykova A.M., et al. Epidemiological features of the incidence and course of the new coronavirus infection Covid-19 in medical workers (based on the analysis of data from patients treated in a repurposed infectious diseases hospital) //Medicine in Kuzbass. 2020;4:21–24. (In Russ). doi: 10.24411/2687-0053-2020-10035

18. Logunov D., Dolzhikova I., Shcheblyakov D., et al. Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–681. doi: 10.1016/S0140-6736(21)00234-8.

19. Babamahmoodi, F., Saeedi, M., Alizadeh-Navaei, R., et al. Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. Sci Rep. 2021;11(21464). doi: 10.1038/s41598-021-00963-7

20. Kirillov I.A., Pirozhkov A.P., Rubtsov V.V., et al. Study of the immunogenicity of the Gam-COVID-Vac vaccine. Biologics. Prevention, diagnosis, treatment. 2022;22(4):435–445. (In Russ). doi: 10.30895/2221-996X-2022-22-4-435-445

21. Nikolaev N.S., Nazarova V.V., Pchelova N.N. et al. About the results of vaccination against COVID-19 employees of the Cheboksary medical organization. Epidemiology and Vaccination Prevention. 2023;22(2):86–94. (In Russ). doi: 10.31631/2073-3046-2023-22-2-86-94

22. Kombarova SY, Aleshkin AV, Novikova LI, et al. Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19. Bull Exp Biol Med. 2022; 173:734–739. doi: 10.1007/s10517-022-05620-1

23. Dolzhikova I.V., Iliukhina A.A., Kovyrshina A.V., et al. Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant. medRxiv. 2021. doi: 10.1101/2021.12.17.21267976

24. Ikegame S., Siddiquey M., Hung C., et al. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nature communications. 2021; 12(1):4598. doi: 10.1038/s41467-021-24909-9

25. Zakurskaya V.Ya., Sizyakina L.P., Kharitonova M.V., Shlyk S.V. Dynamics of specific humoral response in patients who underwent COVID-19. Immunology. 2022; 43 (1): 71–77 (In Russ). doi: 10.33029/0206-4952-2022-43-1-71-77